(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study. The company said the first 55 patients evaluated after six weeks of treatment demonstrated substantial clinical benefit after switching to CREXONT extended-release capsules, including significant increases in daily Good On time, reductions in Off time, improved motor symptom control, and consistent gains in Good On time per doseregardless of whether patients switched from immediate-release carbidopa/levodopa, IR CD/LD with a COMT inhibitor, or RYTARY extended-release capsules.
Amneal will present longer-term outcomes and patient-reported results in 2026 as part of the ongoing, rolling ELEVATE-PD program.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
